Success Stories: EB-1A Approved for Postdoctoral Research Associate in Missouri in the Field of Medicinal Chemistry
Client’s Testimonial:
Thank you so much for the good news. I will recommend your firm to my friends
Position at the Time of Case Filing: Postdoctoral Research Associate
Country of Origin: India
Service Center: Nebraska Service Center (NSC)
State of Residence at the Time of Filing: Missouri
Approval Notice Date: September 4, 2014
Processing Time: 23 Days (9 Days after Premium Processing Requested)
In this case, the client that we had the opportunity to work with was a Postdoctoral Research Associate from India in the field of Medicinal Chemistry. He had conducted his research in the highly specialized area of radiopharmaceutical chemistry, drug discovery, surface chemistry, molecular imaging and molecular biology with a focus on the development of bioactive compounds, ligand-targeted imaging, and therapeutic agents for the diagnosis and treatment of important human diseases. His work had resulted in 8 peer-reviewed scientific articles, 20 patents and numerous presentations at national and international conferences; one of his patent research work developing for FDA approval by a biotechnology company. At the time that his case was filed, his publications had been cited at least 142 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also reviewed 77 manuscripts for distinctive, internationally-circulated journals. His superior level of expertise was confirmed in the following quote from an independent recommender, “[Client] has achieved important results through his research, and has specifically made significant scientific advances toward the effective diagnosis and treatment of prostate and breast cancers.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Medicinal Chemistry, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 23 days.